Evaluation of efficacy of letrozole as a neoadjuvant endocrine therapy in postmenopausal patients with hormone receptor-positive breast cancer

Phase 2

• Conditions: Breast cancer

• Registration Number: JPRN-UMIN000003101
• Lead Sponsor: Tohoku University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-01-28
• Study Completion: 2011-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1. Synchronous or asynchrous bilateral breast cancer. 2. Patients receiving drugs having a potential influence on the status of sex hormones (hormone replacement therapy, raloxifene, etc.). (However, patients after washout for at least 8 weeks can be enrolled.) 3. Patients who are being treated of cerebral infarction at the time of the enrollment. 4. Patients with myocardial infarction or congestive heart failure at the past history, or patients who need treatment of ischemic hear disease, arryhythmia or valvular disorder. 5. Patients within 30 days after completion of treatment with the investigational drugs. 6. Patients whom doctors judged inadequate to the enrollment of this study by other reasons.

Study & Design

• Study Type: Interventional
• Study Design: Not specified